Pfizer signs global licensing deal with 3SBio for bispecific antibody
Pfizer will pay $1.25 upfront, and 3SBio could earn up to $4.8bn in milestone payments.
Japan’s MHLW approves GSK’s Blenrep combos for multiple myeloma
Novo Nordisk’s CEO to step down as weight loss market share plummets
Pharma’s AI prospects get nudged into the future with EU’s AI act
EC approves BMS’ perioperative Opdivo and chemo for NSCLC
BioMarin agrees to acquire Inozyme for $270m
Analysis
View More
Themes
View MoreAre regulators keeping pace with AI adoption in clinical trials?
AI is now used throughout clinical trials, from recruitment to analysis – but are regulators keeping up?
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Recursion axes drug programmes to streamline pipeline
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
3 reasons why biotechs preparing for launch need a compliant content foundation